



Call for Abstracts

DEADLINE: 30 APRIL 2024

Modalities: Oral and Poster Presentations

Important Dates

Event	Date
Deadline for submission	30 April 2024, 11:59 PM (Rome Time Zone)
Notification to Authors	1 June 2024

Guidelines for Abstract submission

Abstracts can only be submitted through the online submission form at website <https://abstract.evsrc.it/>

To access at the submission form is necessary to the username and password of the EGO-System. If you do not have username and password, you can register at the EGO Home Page; username and password will be sent in 2 working days.

Click [HERE](#) to register to EGO Platform

The Corresponding and Presenting authors must be indicated if they are not the same person. The presenting Author must be registered for the Congress. Submitted abstracts will be accepted and published in the Conference Proceedings only upon receipt of payment.

Abstracts based on professional experience from practitioners are encouraged.

A maximum of two papers per author will be accepted.



Characteristics of the Abstract

All abstracts must be written in English.

Abstract should be original study (*Review not allowed*) and based on Clinical research or Case reports.

Abstract based on Clinical research, both oral and poster presentations, must include the ethical approval.

Research must not have been published or accepted for publication by 30 APRIL 2023.

The abstract length should be maximum 3.500 characters including spaces. The title maximum length is 180 characters including spaces.

The ABSTRACT SUBMISSION CENTRE will guide you filling up the following fields:

1. ABSTRACT FORMAT

A single abstract is required: text length should be max. 3.500 characters including spaces.

2. TITLE

Title of work must be in CAPITAL LETTER, maximum length 180 characters including spaces.

3. SUBJECT

4. ADDRESS FOR CORRESPONDENCE

5. AUTHORS

- Max. 7 authors. Mark the presenting author with an asterisk.
- Indicate affiliation to an institute with superscript numbering e.g., Smith T1, Patterson C2.
- Enter institutes in numerical sequence after the parameter <Institution> e.g.
1 XXXXXX, 2XXXXXX

6. TEXT AND BIBLIOGRAPHY

- Introduction and Objectives;
- Materials and Methods;
- Results;
- Conclusions;
- Bibliography (not included in the count of characters)

Images, figures, charts, tables and graphs are NOT allowed in the abstract.

Abbreviations must be defined in the abstract, if applicable. Do not mention names or commercial brands in the title. Authors could include them, in square brackets, in the body of the abstract.



Evaluation of the Abstract

The evaluation will be carried out considering:

- potential scientific value and relevance of the study,
- the originality of the study,
- clear description of the study,
- relation of the methodology with the objectives,
- congruence between results and conclusions,
- ethical considerations,
- correct writing in the English language.

All abstracts are reviewed by the Congress Scientific Committee which reserves the right to select abstracts relevant to the sessions and topics and decides on the final form of the presentation (oral or poster).

The contact author will be notified as of June 1st, 2024 if the abstract has been accepted. Notifications will be sent by e-mail to the addresses indicated during abstract submission. Together with the notification, if the abstract is selected for poster or oral presentation.

The Oral presentation must be presented in English and will have a 13-minute slot (including 3 min for questions/answers) which may not be exceeded.

Manuscripts must contain scientific data and meet international ethical standards.

EV POLICY ON THE USE OF ANIMALS IN RESEARCH

EV's aims are to promote and advance the standards in veterinary species through clinical research and training. We encourage robust clinical and translational research in the area of veterinary podiatry. Such research may often involve prospective or retrospective studies on animals or ex vivo or in vitro studies on animal tissues. Studies on veterinary patients should not involve unnecessary interventions with the sole purpose of research; in other words, all interventions on veterinary patients should be for the intended benefit of the individual animal.

All such research should have local Ethics Committee approval as well as any local, regional or national licences when required; abstracts submitted should state this is the case when indicated.

As society concerned with the health and welfare of animals, EV acknowledges that sometimes research on animals is necessary for the benefit of human and animal health. However, we strongly support the 3R tenets of Russell and Burch, namely 'replacement, refinement and reduction' of animals in research, as supported by the International Council for Laboratory Animal Science (www.iclas.org) and embedded in the European Union Directive 2010/63/EU

(<https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:EN:PDF>)

Moreover, EV will not accept any studies for presentation or publication that involve the use of live bovines and small ruminants, **dogs, cats, horses or non-human** primates in invasive experimentation.